BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19223878)

  • 1. Model-based benefit-risk assessment: can Archimedes help?
    Krishna R
    Clin Pharmacol Ther; 2009 Mar; 85(3):239-40. PubMed ID: 19223878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the cardiovascular safety of diabetes therapies.
    Goldfine AB
    N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
    [No Abstract]   [Full Text] [Related]  

  • 3. Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitus.
    Hennekens CH; Hebert PR; Schneider WR; O'Brien P; Demets D; Borer JS
    Contemp Clin Trials; 2010 Sep; 31(5):411-3. PubMed ID: 20601161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved knowledge of antidiabetic treatment--a necessity for the modern cardiologist.
    Wikström G; Malmberg K; Rydén L
    Eur Heart J; 1999 Mar; 20(6):403-5. PubMed ID: 10213343
    [No Abstract]   [Full Text] [Related]  

  • 5. Considerations for design and data analysis of noninferiority/superiority cardiovascular trials.
    Quan H; Li M; Zhao PL; Cho M; Zhang J; Wu Y
    J Biopharm Stat; 2013; 23(1):239-60. PubMed ID: 23331234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intensive blood glucose lowering to reduce cardiovascular risk: contra].
    Marx N
    Dtsch Med Wochenschr; 2009 May; 134(20):1061. PubMed ID: 19421930
    [No Abstract]   [Full Text] [Related]  

  • 7. [Intensive blood glucose lowering to reduce cardiovascular risk: pro].
    Martin S
    Dtsch Med Wochenschr; 2009 May; 134(20):1060. PubMed ID: 19421929
    [No Abstract]   [Full Text] [Related]  

  • 8. Suboptimal use of cardioprotective drugs in newly treated elderly individuals with type 2 diabetes.
    Sirois C; Moisan J; Poirier P; Grégoire JP
    Diabetes Care; 2007 Jul; 30(7):1880-2. PubMed ID: 17384345
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulatory watch: FDA issues guidance for cardiovascular risk assessment of novel antidiabetic agents.
    Nat Rev Drug Discov; 2009 Feb; 8(2):99. PubMed ID: 19180100
    [No Abstract]   [Full Text] [Related]  

  • 10. Probity gone nuts.
    Nat Biotechnol; 2007 May; 25(5):483. PubMed ID: 17483818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diabetology 2007].
    Scherbaum WA
    Dtsch Med Wochenschr; 2007 Jun; 132(25-26):1407-10. PubMed ID: 17570091
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prevention of type 2 diabetes mellitus: proven and new aspects].
    Ritzel RA; Isermann B; Woerle HJ
    Dtsch Med Wochenschr; 2007 May; 132(19):1057-61. PubMed ID: 17476638
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development.
    Hwang TJ; Franklin JM; Kesselheim AS
    Clin Pharmacol Ther; 2017 Aug; 102(2):290-296. PubMed ID: 28390139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing the start time of statin therapy for patients with diabetes.
    Denton BT; Kurt M; Shah ND; Bryant SC; Smith SA
    Med Decis Making; 2009; 29(3):351-67. PubMed ID: 19429836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a pharmacist-led cardiovascular risk reduction clinic for diabetic patients with and without mental health conditions.
    Taveira TH; Pirraglia PA; Cohen LB; Wu WC
    Prev Cardiol; 2008; 11(4):195-200. PubMed ID: 19476571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Time for a European perspective on cardiovascular prevention].
    Nilsson PM; Perk J; Rydén L
    Lakartidningen; 2008 Apr 2-8; 105(14):1000-4. PubMed ID: 18478749
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis.
    Garrison LP; Towse A; Bresnahan BW
    Health Aff (Millwood); 2007; 26(3):684-95. PubMed ID: 17485745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin: diamonds are forever.
    Papanas N; Maltezos E; Mikhailidis DP
    Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of some antidiabetic drugs.
    Med Lett Drugs Ther; 2017 Aug; 59(1527):136-138. PubMed ID: 28787745
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.